[Expert consensus on the role of hematological markers in the early clinical screening of hepatocellular carcinoma].

The disease burden of hepatocellular carcinoma in our country is serious, and the prognosis is not ideal. Therefore, early screening of high-risk groups of hepatocellular carcinoma through simple methods is the key to achieving early diagnosis and treatment and improving survival. At present, alpha fetoprotein (AFP) and other hematological tests are still the main methods in the early screening of hepatocellular carcinoma, but their sensitivity and specificity are limited, and the risk of missed diagnosis is high. In recent years, with the continuous development of science and technology, the improvement of traditional detection methods and the emergence of new markers such as methylated DNA and miRNA have brought hope for further improving the sensitivity and specificity of early hepatocellular carcinoma screening. This consensus summarizes the research progress of traditional and new hematological examination methods, and puts forward the expert guidance on the role of hematological markers in the early screening of hepatocellular carcinoma; with aim to provide a basis for improving the prevention and control level in China.